HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 617.34 $ 1.34 (0.22 %)

DIA $ 472.15 $ 2.20 (0.47 %)

SPY $ 677.95 $ 1.49 (0.22 %)

TLT $ 91.46 $ -0.10 (-0.11 %)

GLD $ 379.33 $ 0.76 (0.2 %)

Previous Close

$ 66.885

Open

$ 66.75

Bid

$ 66.93 x 54

Ask

$ 66.97 x 212

Day's Range

$ 66.41 - $ 66.95

52 Week Range

$ 42.01 - $ 79.50

Volume

1,430,636

Average Volume

Market Cap

7.82B

Beta (5Y Monthly)

$ 0.93

PE Ratio (TTM)

$ 14.04

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-18-2025	12-31-2024	10-K
4	10-31-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-07-2024	03-31-2024	10-Q
7	02-20-2024	12-31-2023	10-K
8	11-06-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-09-2023	03-31-2023	10-Q
11	02-21-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q
15	02-22-2022	12-31-2021	10-K
16	11-02-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	02-23-2021	12-31-2020	10-K
20	11-02-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-11-2020	03-31-2020	10-Q
23	02-24-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-06-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	02-21-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-10-2018	03-31-2018	10-Q
31	02-20-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-08-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	02-28-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-09-2016	06-30-2016	10-Q
38	05-09-2016	03-31-2016	10-Q
39	02-29-2016	12-31-2015	10-K
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Morgan Stanley Maintains Overweight on Hal...
10/20/2025 15:35:18

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price t...

The Analyst Verdict: Halozyme Therapeutics...
10/15/2025 20:01:22

HC Wainwright & Co. Reiterates Buy on Halo...
10/15/2025 10:31:43

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $...

Leerink Partners Upgrades Halozyme Therape...
10/14/2025 18:22:24

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Underperform to Market Perform and...

HC Wainwright & Co. Maintains Buy on Haloz...
10/02/2025 10:33:51

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

Halozyme To Acquire Elektrofi In Deal Comp...
10/01/2025 11:05:20

Benchmark Maintains Buy on Halozyme Therap...
09/24/2025 12:24:30

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

Forecasting The Future: 7 Analyst Projecti...
09/22/2025 12:02:57

HC Wainwright & Co. Maintains Buy on Haloz...
09/22/2025 10:36:37

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

What 7 Analyst Ratings Have To Say About H...
08/18/2025 20:01:43

Morgan Stanley Maintains Overweight on Hal...
08/18/2025 12:52:31

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...

JP Morgan Maintains Neutral on Halozyme Th...
08/07/2025 19:17:29

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...

What Does the Market Think About Halozyme ...
08/07/2025 18:00:45

JMP Securities Maintains Market Outperform...
08/06/2025 15:09:07

JMP Securities analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the...

HC Wainwright & Co. Maintains Buy on Haloz...
08/06/2025 12:04:34

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

Morgan Stanley Upgrades Halozyme Therapeut...
08/06/2025 11:19:44

Morgan Stanley analyst Vikram Purohit upgrades Halozyme Therapeutics (NASDAQ:HALO) from Equal-Weight to Overweight and raise...

CORRECTION: Halozyme Therapeutics Q2 Adj. ...
08/05/2025 20:03:21

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of...

Halozyme Therapeutics Raises FY2025 Adj EP...
08/05/2025 20:02:20

Halozyme Therapeutics (NASDAQ:HALO) raises FY2025 Adj EPS guidance from $5.30-$5.70 to $6.00-$6.40 vs $5.50 analyst estimate. R...

Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Earnings Outlook For Halozyme Therapeutics
08/04/2025 15:04:24